{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-105688","form_type":"8-K","ticker":"GPCR","cik":"0001888886","company_name":"Structure Therapeutics Inc.","filed_at":"2026-09-08T12:09:26+00:00","discovered_at":"2026-09-08T12:10:00.469879+00:00","generated_at":"2026-09-08T12:10:09.122373+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Structure Therapeutics: ACCG-2671 SAD positive, aleniglipron 72-wk OLE up to 16.2% weight loss","bullets":["ACCG-2671 SAD: 31 healthy adults, ~6-day half-life, no SAEs, 3.3% mean weight loss at Day 24 (10 mg), CTX-1 down ~60%.","Aleniglipron 72-wk OLE: 11.6%/14.4%/16.2% weight loss for 45/90/120 mg arms; >1/3 of 90/120 mg cohorts >20% loss (35.9/40.5 lbs).","Placebo crossover with 2.5 mg start: 9.0% (22.7 lbs) at 36 wks; <5% discontinuation due to AEs; improved GI tolerability.","Phase 3 ACCOMPLISH-1 (3,600) and -2 (1,100) enrolling; topline 2H 2028. ACCG-2671 MAD topline 1H 2027.","Q4 2026 readouts: body composition, T2DM, and SWITCH trial results."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-105688","json":"https://secwatch.observer/filing/0001104659-26-105688.json","markdown":"https://secwatch.observer/filing/0001104659-26-105688.md","text":"https://secwatch.observer/filing/0001104659-26-105688.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/0001104659-26-105688-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1888886/000110465926105688/tm2624945d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-08T12:10:09.122373+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}